CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of colorectal, gastric and pancreatic cancer.
  
  OVERVIEW OF ACTIVITY
  Given the prevalent nature of the disease, extensive resources are allocated to colorectal cancer (CRC) research and education. Interestingly, however, although individually less frequently encountered, the collection of other “non-CRC” gastrointestinal (GI) cancers account for more per annum deaths than those attributed to tumors of the colon and rectum combined. As such, educational opportunities relevant to the clinical management of CRC and the most prevalent non-CRC GI tumors, including gastric and pancreatic cancer, are essential to the general oncologist’s delivery of comprehensive care.
  
  These video proceedings from a CME meeting held during the 2018 Gastrointestinal Cancers Symposium feature review of actual cases of colorectal, gastric and pancreatic cancer from the practice of the moderator and presentations given by leading investigators in the management of GI cancers. By providing information and practical perspectives on important new developments, this activity will address the most pressing educational needs of practitioners involved in the multidisciplinary management of colorectal, gastric and pancreatic cancer.
  
  LEARNING OBJECTIVES

  • Review recent data on therapeutic advances and changing practice standards in colorectal, gastric and pancreatic cancer, and integrate this information, as appropriate, into current clinical care.
  • Develop a long-term care plan for individuals diagnosed with metastatic CRC, considering biomarker profile, tumor location, exposure to prior systemic therapy, symptomatology, performance status (PS) and personal goals of treatment.
  • Use HER2 status, clinical factors and patient perspectives to optimize the selection and sequence of systemic therapy for locally advanced or metastatic gastric/gastroesophageal cancer.
  • Consider age, PS and other clinical and logistical factors in the selection of systemic therapy for patients with localized, locally advanced or metastatic pancreatic adenocarcinoma.
  • Appraise the rationale for and clinical data with commercially available and developmental immune checkpoint inhibitors in the treatment of GI cancers.
  • Describe ongoing research to validate or identify additional biomarkers predictive of response to anti-PD-1/PD-L1 antibodies, and use this information to guide future trial design or routine clinical practice.
  • Recall the design of ongoing clinical trials evaluating novel investigational agents in GI cancers, and counsel appropriately selected patients about availability and participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  Tanios Bekaii-Saab, MD
  Professor, Mayo Clinic College of Medicine and Science
  Co-Leader, GI Cancer Program, Mayo Clinic Cancer Center
  Senior Associate Consultant
  Mayo Clinic, Arizona
  Scottsdale, Arizona
  
  Consulting Agreements: Amgen Inc, ARMO BioSciences, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Exelixis Inc, Genentech BioOncology, Ipsen Biopharmaceuticals Inc, Merck, Roche Laboratories Inc, SillaJen; Contracted Research: Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Lilly.
  
  Peter C Enzinger, MD
  Director, Center for Esophageal and Gastric Cancer
  Assistant Professor of Medicine, Harvard Medical School
  Dana-Farber Cancer Institute
  Boston, Massachusetts
  
  Advisory Committee: Merck; Consulting Agreements: Astellas Pharma Global Development Inc, Five Prime Therapeutics Inc, Merck, Taiho Oncology Inc.
  
  Heinz-Josef Lenz, MD
  Professor of Medicine and Preventive Medicine
  J Terrence Lanni Chair in Cancer Research
  Co-Director, USC Center for Molecular Pathways and Drug Discovery
  Keck School of Medicine, University of Southern California
  Associate Director of Adult Oncology
  Co-Director, Colorectal Center
  Scientific Director, Cancer Genetics Unit
  USC Norris Comprehensive Cancer Center
  Los Angeles, California
  
  Advisory Committee and Consulting Agreements: Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, EMD Serono Inc, Genentech BioOncology, Roche Laboratories Inc; Contracted Research: Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, EMD Serono Inc, Genentech BioOncology, Merck, Roche Laboratories Inc.
  
  Eileen M O'Reilly, MD
  Associate Director, Clinical Research
  David M Rubenstein Center for Pancreatic Cancer Research
  Attending Physician, Member
  Memorial Sloan Kettering Cancer Center
  Professor of Medicine
  Weill Medical College of Cornell University
  New York, New York
  
  Consulting Agreements: Agios Pharmaceuticals Inc, Amgen Inc, Aptus Clinical, ASLAN Pharmaceuticals, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boston Scientific Corporation, Bristol-Myers Squibb Company, CARsgen, CASI Pharmaceuticals Inc, Celgene Corporation, CytomX Therapeutics, Daiichi Sankyo Inc, Debiopharm Group, Delcath Systems Inc, Eisai Inc, Gilead Sciences Inc, Halozyme Inc, Incyte Corporation, Inovio Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Lilly, MabVax Therapeutics, MedImmune Inc, Merck, Onxeo, PCI Biotech, Roche Laboratories Inc, Sanofi Genzyme, Servier, Silenseed Ltd, SillaJen, Sirtex Medical Ltd, Yakult Honsha Co Ltd; Contracted Research: Agios Pharmaceuticals Inc, Array BioPharma Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, CASI Pharmaceuticals Inc, Celgene Corporation, Exelixis Inc, Genentech BioOncology, Incyte Corporation, Lilly, MabVax Therapeutics, MedImmune Inc, Momenta Pharmaceuticals Inc, Novartis, OncoMed Pharmaceuticals Inc, Roche Laboratories Inc.
  
  Michael J Overman, MD
  Associate Professor
  Department of Gastrointestinal Medical Oncology
  Division of Cancer Medicine
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
  
  Consulting Agreements: Bristol-Myers Squibb Company, MedImmune Inc, Roche Laboratories Inc, Sirtex Medical Ltd; Contracted Research: Amgen Inc, MedImmune Inc, Roche Laboratories Inc, Sirtex Medical Ltd; Other Remunerated Activities: Merck.
  
  MODERATOR
  
  Johanna C Bendell, MD
  Director, GI Oncology Research
  Associate Director, Drug Development Unit
  Sarah Cannon Research Institute
  Nashville, Tennessee
  
  Contracted Research: Abbott Laboratories, AbbVie Inc, Agios Pharmaceuticals Inc, Apexigen, ARMO BioSciences, Array BioPharma Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Celldex Therapeutics, CytomX Therapeutics, Daiichi Sankyo Inc, Eisai Inc, EMD Serono Inc, Five Prime Therapeutics Inc, Forty Seven Inc, Genentech BioOncology, Gilead Sciences Inc, GlaxoSmithKline, Incyte Corporation, Kolltan Pharmaceuticals Inc, Leap Therapeutics Inc, Lilly, MacroGenics Inc, MedImmune Inc, Merck, Nektar, Novartis, OncoMed Pharmaceuticals Inc, Onyx Pharmaceuticals, an Amgen subsidiary, Roche Laboratories Inc, Sanofi Genzyme, Stemcentrx, SynDevRx Inc, Taiho Oncology Inc, Takeda Oncology.
  
  AUDIENCE ENGAGEMENT LIAISON — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.
  
  RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Halozyme Inc, Ipsen Biopharmaceuticals Inc, Lilly and Taiho Oncology Inc.
  
  Hardware/Software Requirements:
  A high-speed Internet connection
  A monitor set to 1280 x 1024 pixels or more
  Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
  Adobe Flash Player 27 plug-in or later
  Adobe Acrobat Reader
  (Optional) Sound card and speakers for audio
  
  Last review date: March 2018
  Expiration date: March 2019